Clinical Trials Browser

Observational × alectinib × Clear all

NCT06862869 2026-05-05

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Carcinoma, Non-Small-Cell Lung

NCT05525858 2025-04-27

KOSMOSII

Neoplasm Metastasis

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04351334 2024-09-19

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

161 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Carcinoma, Non-Small-Cell Lung

NCT06339554 2024-04-01

TOSS-ALK

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT03271554 2022-11-18

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Carcinoma, Non-Small-Cell Lung

NCT04708639 2021-02-02

MonAlec

Lung Neoplasms, Disease Resistance

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung